Navigation Links
Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Date:11/3/2011

and low-dose Qnexa, respectively, compared to 2.1% in the placebo group (p<0.0001);
  • In the ITT-LOCF analysis, LS mean percent weight loss at week 56 was 10.9%* and 5.1%* for the top and low dose, respectively, as compared to 1.6% for the placebo group (p<0.0001);
  • Among patients who completed the top-dose course of treatment, 83.5% lost >/= 5%; 67.7% lost >/= 10%; and 48.1% lost >/= 15% of their baseline weight;
  • Categorical weight loss from baseline (ITT-LOCF) was:

  • >/= 5%

    >/= 10%

    >/= 15%Top dose

    67%*

    47%*

    32%*Low dose

    45%*

    19%*

    7%+Placebo

    17%

    7%

    3%*p<0.0001 vs placebo+p < 0.05 vs placeboA significantly greater number of patients completed one year of treatment in the Qnexa groups, top dose (66%) and low dose (61%), as compared to the placebo group (53%). The most commonly reported side effects were tingling, dry mouth, constipation and altered taste. Rates of serious adverse events were the same across treatment groups. Most adverse events were seen early in treatment and there was a low dropout rate due to adverse events, 16.0% and 11.3% for top and low dose, respectively, compared to 8.4% for placebo.

    About the EQUIP StudyThe EQUIP study included 1,267 severely obese patients (1,050 females and 217 males) with an overall mean age of 42.7 years; mean BMI of 42.0 kg/m2; and mean baseline weight of 256 pounds. Eligibility criteria included age 18-70 years; BMI >/= 35 kg/m2 (no upper limit); triglycerides </= 200 mg/dl with treatment of 0-1 lipid-lowering medication; BP </= 140/90mm Hg with treatment of <3 anti-hypertensive medications; and fasting serum glucose level </= 110 mg/dl.

    The study was a randomized, double-blind, placebo-controlled, 3-arm, prospective trial with patients randomized to receive once-a-day treatment with low-dose Qnexa, top-dose Qnexa or placebo.
    '/>"/>

    SOURCE VIVUS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
    2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
    3. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
    4. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
    5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
    6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
    7. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
    8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
    9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
    10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
    11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/17/2014)... , Oct. 17, 2014  Talyst, a market ... 2014 LeadingAge Annual Meeting in Nashville, TN. ... System, the market leading solution for onsite, remote medication ... term care facilities to safely and securely dispense medication ... to first dose, helps ensure that the correct medication ...
    (Date:10/17/2014)... , Oct. 17, 2014  Ameritox SM , ... the appointment of Thomas Smith , M.D., as ... a field-based team offering scientific resources for healthcare providers, ... has held leadership positions at a variety of healthcare ... benefit both the pain and behavioral health sides of ...
    (Date:10/17/2014)... 2014   DaVita HealthCare Partners Inc. ... nation,s largest and most innovative health care communities, ... the company,s award-winning, leadership development and cultural orientation ... from around the globe were in attendance for ... is a two-day one-of-a-kind experience for new and ...
    Breaking Medicine Technology:Talyst Exhibits at LeadingAge Annual Meeting 2Ameritox Appoints New Chief Medical Officer 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3
    ... Naurex Inc., a clinical-stage company developing innovative ... today announced that it has initiated a Phase II ... Glycine-site Functional Partial Agonist (GFPA) selective modulator of the ... therapy for patients who are not achieving an adequate ...
    ... 2011 Cempra Pharmaceuticals Inc. today announced that ... present at the 2011 Wells Fargo Healthcare Conference at ... Fernandes will provide an overview of the company,s two ... and other infections and TAKSTA™ for the oral treatment ...
    Cached Medicine Technology:Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 2Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 3
    (Date:10/20/2014)... 2014 Final Cut Pro X Plugin developers ... Citrus theme for FCPX filmmakers . , “Fun, cool, ... the Citrus theme” Says Christina Austin, CEO of Pixel Film ... professional.” , Citrus comes with all the tools needed for ... four transitions for added style, a title screen for an ...
    (Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
    (Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... his innovative True Form Tummy Tuck® method ... faculty at The University of Texas Medical Branch ... a medical student. Patronella, who is a founding partner ... practices in Texas, The Aesthetic Center for Plastic ...
    (Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury law ... greater Phoenix area and across Arizona reports record demand ... automobile accidents. Statistics have indicated a steady increase in ... such, Hastings and Hastings has seen a steady increase ... have been injured through no fault of their own ...
    (Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular suppliers ... bamboo deckings . Moreover, the company has launched ... now available at deeply discounted rates. , As ... overstate the significance of online business nowadays. Thus, BambooIndustry.com ... company’s workers are striving to deliver both value and ...
    Breaking Medicine News(10 mins):Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
    ... gave physicians seemingly miraculous weapons against infectious disease. ... and tuberculosis were suddenly at hand. Moreover, many ... versatile enough to knock out a wide range ... a fundamental limitation: They,re useless against viruses, which ...
    ... team from the National Taiwan University Hospital has evaluated ... models severely damaged by two kinds of chemical toxicity ... to efficiently repopulate the toxin-induced, severely damaged livers. The ... double issue of Cell Transplantation (18:10/11) and ...
    ... Surgeons who engage in minimally invasive, laparoscopic surgery are ... their own detriment. That,s the finding of the largest ... perform laparoscopic procedures. The survey, developed at the University ... 87 percent of laparoscopic surgeons have experienced physical symptoms ...
    ... ... Integration and Strong Business Intelligence Allows for Real-Time Monitoring and Better Decision Making ... ... integration and interoperability solutions, announced today it has entered a strategic partnership agreement ...
    ... ... of managed network services to help regional SMBs build a solid IT foundation to ... ... provider of managed IT services for Texas-based small- and medium-sized businesses, today ...
    ... , , , , BEIJING , ... or the "Company"), a leading China -based vaccine manufacturer,announced today ... exercised in full their option to purchase an,additional 1,500,000 common shares ... and sell a total of 11,500,000 common shares,at $5.75 ...
    Cached Medicine News:Health News:Compound found that targets wide range of viruses 2Health News:Beyond liver transplants: Acutely damaged livers may be repaired via transplanted hepatocytes 2Health News:Survey finds many surgeons suffer injuries from minimally invasive techniques 2Health News:Survey finds many surgeons suffer injuries from minimally invasive techniques 3Health News:Survey finds many surgeons suffer injuries from minimally invasive techniques 4Health News:BridgeGate and Information Builders form Strategic Partnership to Extend Integration Capability for Healthcare and Government Markets 2Health News:BridgeGate and Information Builders form Strategic Partnership to Extend Integration Capability for Healthcare and Government Markets 3Health News:Pivot Networks and Brookside Technology Partners, Inc. Team to Broaden Managed IT Services Offering for Texas SMBs 2Health News:Pivot Networks and Brookside Technology Partners, Inc. Team to Broaden Managed IT Services Offering for Texas SMBs 3Health News:Sinovac Announces Exercise of Over-Allotment Option 2Health News:Sinovac Announces Exercise of Over-Allotment Option 3
    Gentamicin is an aminoglycosidic antibiotic that inhibits bacterial growth by inhibiting protein synthesis. Gentamicin is used for prevention and elimination of bacterial contaminants in cell culture...
    LB Agar plates with 10mM Magnesium Sulfate....
    LB Agar plates with 0.1mM EDTA....
    1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
    Medicine Products: